Interestingly, treatment with bevacizumab influences ET-1 plasma level63,64 and is of greater benefit for those ovarian cancer patients with the mesenchymal subtype65 in which ETAR and ZEB1 are overexpressed. Here, EDN1 is linked to ovarian carcinoma.